Charles Schwab
IRLA

Charles Schwab’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Charles Schwab’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-55
Closed -$8.26K – 3565
2024
Q2 		$8.26K Hold
55
– – ﹤0.01% 3619
2024
Q1 		$11.7K Hold
55
– – ﹤0.01% 3457
2023
Q4 		$11.6K Hold
55
– – ﹤0.01% 3517
2023
Q3 		$12.3K Hold
55
– – ﹤0.01% 3551
2023
Q2 		$16.6K Hold
55
– – ﹤0.01% 3578
2023
Q1 		$17.2K Hold
55
– – ﹤0.01% 3517
2022
Q4 		$7.02K Hold
55
– – ﹤0.01% 3541
2022
Q3 		$15K Sell
55
-433
-89% -$165K ﹤0.01% 3494
2022
Q2 		$217K Sell
488
-95
-16% -$67.2K ﹤0.01% 3232
2022
Q1 		$723K Sell
583
-47
-7% -$64K ﹤0.01% 2979
2021
Q4 		$1.59M Buy
630
+9
+1% +$54.9K ﹤0.01% 2774
2021
Q3 		$11.4M Buy
621
+92
+17% +$1.46M ﹤0.01% 1931
2021
Q2 		$5.61M Buy
529
+50
+10% +$419K ﹤0.01% 2294
2021
Q1 		$3.45M Buy
479
+18
+4% +$130K ﹤0.01% 2468
2020
Q4 		$2.56M Buy
461
+1
+0.2% +$8.86K ﹤0.01% 2528
2020
Q3 		$4.6M Buy
460
+176
+62% +$1.6M ﹤0.01% 2099
2020
Q2 		$2.63M Buy
284
+66
+30% +$605K ﹤0.01% 2321
2020
Q1 		$1.99M Buy
218
+3
+1% +$29.6K ﹤0.01% 2279
2019
Q4 		$2.41M Buy
215
+92
+75% +$555K ﹤0.01% 2363
2019
Q3 		$612K Sell
123
-1
-0.8% -$6.15K ﹤0.01% 2722
2019
Q2 		$1.05M Buy
+124
New +$741K ﹤0.01% 2560

Other funds holding IRLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Charles Schwab's IRLA Position: Q3 2024 in Review

Charles Schwab sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2024, closing a stake of 55 shares — an estimated $8.26K sold.

Charles Schwab first reported a position in IRLA in Q2 2019 and held it in 21 quarters. The position peaked at $11.4M in Q3 2021. 32 funds tracked by Wall St. Rank hold IRLA as of Q3 2024.

  • Charles Schwab reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 55 IRulya Therapeutics Inc. Common Stock shares in Q3 2024, an estimated $8.26K.
  • Charles Schwab first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 21 quarters.
  • Charles Schwab's IRulya Therapeutics Inc. Common Stock position peaked at $11.4M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.